When you notice returning appetite, reduced satiety after meals, or stalled weight loss for 2 or more weeks, these are clinical indicators your nervous system may have partially adapted to your present dose
Preclinical data suggests that Amylin biology may favour a much more fat-loss selective ratio
If this occurs, contact your doctor to receive proper care
Our high-quality supplementation helps ensure you have a safe and successful weight loss journey while mitigating side effects
In clinical trials: Semaglutide: Approximately 7% discontinued due to adverse events Tirzepatide: Approximately 4-7% discontinued due to adverse events (dose dependent) Retatrutide: Approximately 6-10% discontinued due to adverse events (dose dependent) These rates are relatively close, suggesting that despite the differences in mechanism and side effect profiles, all three medications are tolerable for the vast majority of people who start them
This will depend on their overall health conditions, adherence to their weight management plan, and other factors
